Krystal Biotech, Inc. (KRYS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	470.0M	389.1M	290.5M	50.7M	—
Cost of Revenue	31.2M	28.8M	20.1M	3.1M	—
Gross Profit	438.8M	360.4M	270.5M	47.6M	—
Operating Expenses
R&D Expense	60.9M	58.0M	53.6M	46.4M	42.5M
SG&A Expense	155.9M	146.7M	113.7M	98.4M	77.7M
General & Admin Expense	41.0M	—	—	—	77.7M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(5.7M)	(5.7M)	37.5M	12.5M	25.0M
Total Operating Expenses	211.1M	199.1M	204.8M	157.3M	145.2M
Cost and Expenses	242.3M	227.8M	224.8M	160.4M	145.2M
Operating Income (EBIT)	227.7M	161.3M	65.7M	(109.7M)	(145.2M)
Non-Operating
Interest Income	1.4M	28.2M	29.7M	22.6M	5.2M
Interest Expense	—	—	—	—	—
Net Interest Income	1.4M	28.2M	29.7M	22.6M	5.2M
Other Non-Op Income/Expense	31.1M	28.2M	29.7M	122.6M	5.2M
Non-Operating Income (excl Interest)	(17.8M)	(28.2M)	(37.5M)	(12.5M)	(25.0M)
EBT (Pre-Tax Income)	258.8M	189.5M	95.4M	12.9M	(140.0M)
Income Tax Expense	33.6M	(15.4M)	6.2M	2.0M	—
Bottom Line
Net Income	225.2M	204.8M	89.2M	10.9M	(140.0M)
Earnings from Cont. Ops	225.2M	204.8M	89.2M	10.9M	(140.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	225.2M	204.8M	89.2M	10.9M	(140.0M)
Per Share
Basic EPS	$7.66	$7.08	$3.12	$0.40	($5.49)
Diluted EPS	$7.37	$6.84	$3.00	$0.39	($5.49)
Revenue Per Share	$15.87	$13.44	$10.16	$1.87	$0.00
Shares
Basic Shares Outstanding	29.6M	28.9M	28.6M	27.2M	25.5M
Diluted Shares Outstanding	30.8M	30.0M	29.7M	27.8M	25.5M
Profitability Metrics
EBITDA	252.3M	196.0M	109.9M	(92.2M)	(116.1M)
D&A	6.7M	6.6M	6.7M	5.0M	4.1M
EBIT	245.5M	189.5M	103.2M	(97.2M)	(120.2M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026